Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study.

Anxiety involves complex, incompletely understood interactions of genomic, environmental, and experience-derived factors, and is currently being measured by psychological criteria. Here, we report previously nonperceived interrelationships between expression variations and nucleotide polymorphisms of the chromosome 7q21-22 acetylcholinesterase-paraoxonase 1 (ACHE-PON1) locus with the trait- and state-anxiety measures of 461 healthy subjects from the Health, Risk Factors, Exercise Training, and Genetics Family Study. The AChE protein controls the termination of the stress-enhanced acetylcholine signaling, whereas the PON protein displays peroxidase-like activity, thus protecting blood proteins from oxidative stress damages. Serum AChE and PON enzyme activities were both found to be affected by demographic parameters, and showed inverse, reciprocal associations with anxiety measures. Moreover, the transient scores of state anxiety and the susceptibility score of trait anxiety both appeared to be linked to enzyme activities. This finding supported the notion of corresponding gene expression relationships. Parallel polymorphisms in the ACHE and PON1 genes displayed apparent associations with both trait- and state-anxiety scores. Our findings indicate that a significant source of anxiety feelings involves inherited and acquired parameters of acetylcholine regulation that can be readily quantified, which can help explaining part of the human variance for state and trait anxiety.

[1]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[2]  Charles D. Spielberger,et al.  Anxiety: Current Trends in Theory and Research , 1972 .

[3]  A. Black.  Functions of the septo-hippocampal system , 1978, Nature.

[4]  J. Gray,et al.  Précis of The neuropsychology of anxiety: An enquiry into the functions of the septo-hippocampal system , 1982, Behavioral and Brain Sciences.

[5]  W. Maclean,et al.  Transient Entrainment and Interruption of the Atrioventricular Bypass Pathway Type of Paroxysmal Atrial Tachycardia: A Model for Understanding and Identifying Reentrant Arrhythmias , 1983, Circulation.

[6]  M. L. Blettel.  Effect of Rate on Left Ventricular Volumes and Ejection Fraction During Chronic Ventricular Pacing , 1983, Circulation.

[7]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[8]  P. McCullagh,et al.  Generalized Linear Models , 1992 .

[9]  A. Gnatt,et al.  Anionic site interactions in human butyrylcholinesterase disrupted by two single point mutations. , 1990, The Journal of biological chemistry.

[10]  O. Lockridge,et al.  Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism. , 1993, American journal of human genetics.

[11]  K. Kendler,et al.  Twin studies of psychiatric illness. Current status and future directions. , 1993, Archives of general psychiatry.

[12]  I. Silman,et al.  Oxidative stress transforms acetylcholinesterase to a molten-globule-like state. , 1994, Biochemical and biophysical research communications.

[13]  N. Risch,et al.  A comparison of linkage disequilibrium measures for fine-scale mapping. , 1995, Genomics.

[14]  J. Wilmore,et al.  The HERITAGE family study. Aims, design, and measurement protocol. , 1995, Medicine and science in sports and exercise.

[15]  David Glick,et al.  Genetic predisposition to adverse consequences of anti–cholinesterases in ‘atypical’ BCHE carriers , 1995, Nature Medicine.

[16]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[17]  M. Keifer,et al.  The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin , 1996, Nature Genetics.

[18]  J. Borovička,et al.  Regulation of gastric and pancreatic lipase secretion by CCK and cholinergic mechanisms in humans. , 1997, The American journal of physiology.

[19]  T. Robbins,et al.  Central cholinergic systems and cognition. , 1997, Annual review of psychology.

[20]  S. File,et al.  Endogenous acetylcholine in the dorsal hippocampus reduces anxiety through actions on nicotinic and muscarinic1 receptors. , 1998, Behavioral neuroscience.

[21]  B. La Du,et al.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. , 1998, The Journal of clinical investigation.

[22]  D. Kaufer,et al.  Acute stress facilitates long-lasting changes in cholinergic gene expression , 1998, Nature.

[23]  M. Krasowski,et al.  Cholinesterase Inhibition by Potato Glycoalkaloids Slows Mivacurium Metabolism , 2000, Anesthesiology.

[24]  The PON1 gene and detoxication. , 2000, Neurotoxicology.

[25]  M. Shapira,et al.  A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. , 2000, Human molecular genetics.

[26]  G. Jarvik,et al.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. , 2001, American journal of human genetics.

[27]  H. Soreq,et al.  Acetylcholinesterase — new roles for an old actor , 2001, Nature Reviews Neuroscience.

[28]  D. Weinberger.  Anxiety at the frontier of molecular medicine. , 2001, The New England journal of medicine.

[29]  G. Biggio,et al.  Long-term treatment with antidepressant drugs reduces the sensitivity of cortical cholinergic neurons to the activating actions of stress and the anxiogenic drug FG 7142 , 2001, Neuropharmacology.

[30]  F. Sánchez-Santed,et al.  Effects of chlorpyrifos in the plus‐maze model of anxiety , 2001, Behavioural pharmacology.

[31]  E A Mayer,et al.  Depression, anxiety, and the gastrointestinal system. , 2001, The Journal of clinical psychiatry.

[32]  D. Kaufer,et al.  Alternative Splicing and Neuritic mRNA Translocation Under Long-Term Neuronal Hypersensitivity , 2002, Science.

[33]  J. Lépine,et al.  The epidemiology of anxiety disorders: prevalence and societal costs. , 2002, The Journal of clinical psychiatry.

[34]  M. Battaglia,et al.  Beyond the usual suspects: a cholinergic route for panic attacks , 2002, Molecular Psychiatry.

[35]  M. Egan,et al.  Serotonin Transporter Genetic Variation and the Response of the Human Amygdala , 2002, Science.

[36]  C. Bouchard,et al.  G protein β3 polymorphism and hemodynamic and body composition phenotypes in the HERITAGE Family Study , 2002 .

[37]  H. Soreq,et al.  Interaction of “readthrough” acetylcholinesterase with RACK1 and PKCβII correlates with intensified fear-induced conflict behavior , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Kevin J. Tracey,et al.  The inflammatory reflex , 2002, Nature.

[39]  A. Gewirtz,et al.  Nucleic-acid therapeutics: basic principles and recent applications , 2002, Nature Reviews Drug Discovery.

[40]  M. Cogné,et al.  Paraoxonase 1 192/55 Gene Polymorphisms in Alzheimer's Disease , 2002, Annals of the New York Academy of Sciences.

[41]  Importance of Blood Pressure Reduction to Protect Organ Damage , 2003 .

[42]  H. Anisman,et al.  Cytokines, stress and depressive illness: brain‐immune interactions , 2003, Annals of medicine.

[43]  G. Jarvik,et al.  Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. , 2003, Annual review of medicine.

[44]  R. Roubenoff.  Catabolism of aging: is it an inflammatory process? , 2003, Current opinion in clinical nutrition and metabolic care.

[45]  K. Shimada,et al.  Effects of phase III cardiac rehabilitation programs on health-related quality of life in elderly patients with coronary artery disease: Juntendo Cardiac Rehabilitation Program (J-CARP). , 2003, Circulation journal : official journal of the Japanese Circulation Society.

[46]  P. Desjardins,et al.  Anticipatory Anxiety in Moderately to Highly-Anxious Oral Surgery Patients as a Screening Model for Anxiolytics: Evaluation of Alprazolam , 2003, Journal of clinical psychopharmacology.

[47]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[48]  D. Treit,et al.  Septal gabaergic and hippocampal cholinergic systems interact in the modulation of anxiety , 2003, Neuroscience.

[49]  E. Väisänen,et al.  The role of the sympathetic nervous system in anxiety: Is it possible to relieve anxiety with endoscopic sympathetic block? , 2003, Nordic journal of psychiatry.

[50]  P. Bennett,et al.  An investigation into the relationship between salivary cortisol, stress, anxiety and depression , 2003, Biological Psychology.

[51]  H. Soreq,et al.  The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  T. Ishimitsu,et al.  Relation of CYP11B2 Gene Polymorphism to the Incidence of Cardiovascular Diseases in Chronic Hemodialysis Patients , 2003 .

[53]  I. Saito,et al.  Association of body mass index, body fat, and weight gain with inflammation markers among rural residents in Japan. , 2003, Circulation journal : official journal of the Japanese Circulation Society.

[54]  D. Shih,et al.  Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. , 2003, Free radical biology & medicine.